Trial Profile
Phase I and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2'-Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Gastrointestinal Cancers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Ropidoxuridine (Primary)
- Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Liver cancer; Oesophageal cancer; Pancreatic cancer; Squamous cell cancer
- Focus Adverse reactions; First in man
- 30 Nov 2022 Status changed from active, no longer recruiting to completed, according to a Shuttle Pharmaceuticals media release.
- 15 Nov 2022 Status changed from active, no longer recruiting to completed, according to a Shuttle Pharmaceuticals media release.
- 23 Jul 2019 Results from metastatic GI cancers population published in the Clinical Cancer Research